How Can Myeloma Patients Facing Disparities Be More Proactive in Their Care?

Dr. Victoria Vardell of the Huntsman Cancer Institute of Utah discusses her study where key findings reveal Black patients are less likely to receive a stem cell transplant (SCT) and encourages patients to ask questions of their providers until they have a complete understanding.

ASH2019, Victoria Vardell MD, Black myeloma patients, SCT, Huntsman Cancer Institute, University of Utah, Diverse Health Hub

About this expert

Victoria Vardell, MD

Division of Hematology and Hematologic Malignancies

Huntsman Cancer Institute, University of Utah

Transcript

Dr. Victoria Vardell:
Multiple Myeloma is as an interesting disease in that it is much more likely to impact Black patients, which is one reason it's interesting to find that Black patients are less likely to receive stem cell transplants and other upfront therapies that are highly recommended. 

Dr. Victoria Vardell:
One of the best things that patients can do is always ask questions. It's easy as physicians to think that someone is understanding what you're saying or understanding what you've known for years, but Multiple Myeloma and many cancers are very confusing and complex diseases. And the therapies are becoming more and more complex as well, so patients can benefit a lot from asking questions, not being afraid to ask them multiple times until they are fully understanding it. And also finding out what resources are available. At many of these large cancer institutes, the resources available for patients are very large, we are always very happy to educate our patients and that's the best way that they can make educated decisions going forward in their treatment.

 

Related Content

pavlos_msaouel.jpg.resize.405.575_edited

Microcosms of Injustice Found Throughout Sickle Cell Disease

Dr. Campbell describes the inequities and injustices throughout the sickle cell community. He presents an example of a patient who almost died because she was not listened to. Physicians must listen to patients with sickle cell disease because their complaints may be a preceding symptom of severe complications.

pavlos_msaouel.jpg.resize.405.575_edited

Is Sickle Cell Disease a Genetic Defense Against COVID-19?

Dr. Msaouel answers questions from the Sickle Cell community. If the disease or trait evolved as a defense against Malaria, does the reported effectiveness of anti-malaria drugs like hydroxychloroquine (Plaquenil) mean that sickle cell patients have natural resistance to the novel coronavirus, COVID-19?

pavlos_msaouel.jpg.resize.405.575_edited

Are Sickle Cell Disease Patients More Susceptible to Renal Medullary Carcinoma?

Dr. Pavlos Msaouel of The University of Texas MD Anderson Cancer Center discusses whether patients with sickle cell disease or who carry the sickle cell trait may be at increased risk for renal medullary carcinoma (RMC).

The information on Diverse Health Hub is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the expert advice of your healthcare team.

© 2020 Diverse Health Hub